Mezzion Pharma
140410.KQ
61.65 USD
1.17
+1.93%
m
Overview
Last close
61.65 usd
Market cap
526.89M usd
52 week high
71.37 usd
52 week low
17.68 usd
Target price
264.22 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
345.2239
Price/Book Value
72.0244
Enterprise Value
1.81B usd
EV/Revenue
344.8213
EV/EBITDA
-15.9681
Key financials
Revenue TTM
20.47M usd
Gross Profit TTM
2.51M usd
EBITDA TTM
-13.09M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
62.74M usd
Net debt
N/A usd
About
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
- Symbol140410.KQ
- ExchangeKQ
- IsinKR7140410002
- CountrySouth Korea
- SectorHealthcare
- IndustryPharmaceuticals
- CEOMr. Dong-Hyun Park
- HeadquarterSeoul
- Web sitehttps://www.mezzion.co.kr
